Relationship between mean blood glucose and glycated haemoglobin in Type 2 diabetic patients

Diabetic Medicine

Volumn 25, Issue 2, 2008, Pages 174-178

  Makris, K ^a   Spanou, L ^a   Rambaouni Antoneli, A ^b   Koniari, K ^a   Drakopoulos, I ^a   Rizos, D ^c   Haliassos, A ^d  

^a KAT HOSPITAL   (Greece)

^b Diabetes Care Centre   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d Greek National External Quality Assessment Scheme in Clinical Chemistry   (Greece)

Author keywords

HbA1c; Mean blood glucose; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GLUCOSE ASSAY; GLUCOSE BLOOD LEVEL; GREECE; GROUPS BY AGE; HEMOGLOBIN DETERMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; SELF EXAMINATION; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; EPIDEMIOLOGIC METHODS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED;

EID: 39749186692     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02379.x     Document Type: Article

References (27)

1. IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels : International Diabetes Federation, 2005.
2. ADA Position Statement. Standards of Medical Care in Diabetes. Diabetes Care 2007 30 (Suppl 1 4 41.
3. Welschen LMC, Bloemendal E, Nijpels G, Dekker JN, Heine RJ, Stalman WAB et al. Self-monitoring of blood glucose in patients who are not using insulin: a systematic review. Diabetes Care 2005 28 : 1510 1517.
4. Ipp E, Aquino RL, Christenson P. Point: self-monitoring of blood glucose in Type 2 diabetic patients not receiving insulin: the sanguine approach. Diabetes Care 2005 28 : 1528 1530.
5. Davidson MB. Counterpoint: self-monitoring of blood glucose in Type 2 diabetic patients not receiving insulin: a waste of money. Diabetes Care 2005 28 : 1531 1533.
6. The Diabetes Control Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329 : 977 986.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 853.
8. 1c determinations. Clin Chem Lab Med 1998 36 : 299 308.
9. 1c in human blood. Clin Chem Lab Med 2002 40 : 78 89.
10. 1c in human blood and the national standardization schemes in the United States, Japan and Sweden: a method comparison study. Clin Chem 2004 50 : 166 174.
11. 1c assay. Diabetologia 2004 47 : R53 54.
12. Svendson PA, Lauritzen T, Soegaard U, Nrup J. Glycosylated haemoglobin and steady-state mean blood glucose concentration in Type 1 (insulin-dependent) diabetes. Diabetologia 1982 23 : 403 405.
13. Nathan DM, Singer DE, Hurxthal K, Goodson JG. The clinical information value of the glycosylated hemoglobin assay. N Eng J Med 1984 310 : 341 346.
14. 1c in the Diabetes Control and Complications Trial. Diabetes Care 2002 25 : 275 278.
15. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002 48 : 436 472.
16. 1c determination. Diabetologia 2004 47 : 1143 1148.
17. Little R. Glycated Hemoglobin Standardization - National Glycohemoglobin Standardization Program (NGSP) Perspective. Clin Chem Lab Med 2003 41 : 1191 1198.
18. 1c results affects metabolic control. Diabetes Care 2002 25 : 2110 2111.
19. 1c'. Clin Chem Lab Med 2007 45 : 1081 1082.
20. Svendson PA, Lauritzen T, Soegaard U, Nerup J. Glycosylated haemoglobin and steady-state mean blood glucose concentration in Type 1 (insulin-dependent) diabetes. Diabetologia 1982 23 : 403 405.
21. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in Type 2 diabetes. Diabetes Care 1997 20 : 1822 1826.
22. 1c interrelationships in Type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care 2001 24 : 2023 2029.
23. Yudkin JS, Forrest RD, Jackson CA, Ryle AJ, Davie S, Gould BJ. Unexplained variability of glycated hemoglobin in non-diabetic subjects not related to glycemia. Diabetologia 1990 33 : 208 215.
24. Kilpatrick ES, Maylor PW, Keevil BG. Biological variation of glycated hemoglobin: implications for diabetes screening and monitoring. Diabetes Care 1998 21 : 261 264.
25. 1c: implications for the assessment of glycaemic control. Clin Chem 2007 53 : 897 901.
26. Virtue MA, Furne JK, Nuttall FQ, Levitt MD. Relationship between GHb concentration and erythrocyte survival determined from breath carbon monoxide concentration. Diabetes Care 2004 27 : 931 935.
27. 1c levels are genetically determined even in Type 1 diabetes: evidence from healthy and diabetic twins. Diabetes 2001 50 : 2858 2863.